Topical corticosteroids early in bacterial keratitis may improve vision

Article

Research from the University of California, San Francisco, found that adding topical corticosteroids two to three days after starting topical antibiotics for the treatment of bacterial keratitis is linked to improved vision, according to a study recently published in JAMA Ophthalmology.

San Francisco-Research from the University of California, San Francisco, found that adding topical corticosteroids two to three days after starting topical antibiotics for the treatment of bacterial keratitis is linked to improved vision, according to a study recently published in JAMA Ophthalmology

The study assessed the timing of the administration of corticosteroids in a subgroup analysis of the Steroids for Corneal Ulcers Trial (SCUT), a randomized, double-masked, placebo-controlled trial that overall found no effect of adding topical corticosteroids to topical moxifloxacin hydrochloride in bacterial keratitis.

The researchers assessed the effect of topical corticosteroids (vs. placebo) on three-month best spectacle-corrected visual acuity in patients who received the treatment or placebo earlier (two to three days after starting topical antibiotics) vs. later (four days or later after starting topical antibiotics). The group also analyzed subgroups of patients with non-Nocardia keratitis and those with no topical antibiotic use before enrollment.

The patients who received the topical corticosteroids earlier had approximately one-line better visual acuity at three months than those given the placebo. In patients who were given the topical corticosteroids later had one-line worse visual acuity at three months compared to those in the placebo group.

The study states, “There may be a benefit with adjunctive topical corticosteroids if application occurs earlier in the course of bacterial corneal ulcers.”

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.